These results demonstrated that, in a dataset of 159 patients, tumor-associated HSPC subsets are predictive for clinical outcomes in glioblastoma, associate with an immunosuppressive phenotype, with hematopoietic niche factors and with specific cancer-promoting cytokines and chemokines. This evidence concerns the gene PSMA7 and glioblastoma.